Paper Details

  1. Home
  2. Paper Details

Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.

Author: , AndrieuJean-Marie, ArakelyanNina, BerthouChristian, ColonnaPierre, DelwailVincent, DesablensBernard, JaisJean-Philippe, MolesMarie-Pierre, QuittetPhilippe, de GuibertSophie

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared two intensive chemotherapy regimens in patients with high-risk Hodgkin lymphoma. The standard ABVD regimen has a 60-70% 5-year freedom from treatment failure rate, but this study aimed to improve outcomes with more intensive regimens.
Paper Details　
Original Abstract of the Article :
The 5-year freedom from treatment failure (FFTF) rate, with treatment failure defined as the lack of post-treatment complete remission (CR), recurrence, or death, ranges from 60% to 70% after 6 to 8 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), which is the referenc...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/cncr.23979

データ提供：米国国立医学図書館（NLM）

The Quest for Optimal Treatment for High-Risk Hodgkin Lymphoma

In the vast desert of [Hematologic Malignancies], we are constantly seeking more effective and less toxic treatments. This study delves into the complex world of Hodgkin lymphoma (HL), focusing on patients with high-risk disease. Researchers compared two intensive chemotherapy regimens, one involving 3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy and the other involving 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation. This study aims to identify the most effective and tolerable treatment approach for high-risk HL.

Finding the Right Path to Recovery

This research explores the effectiveness of different treatment approaches for high-risk Hodgkin lymphoma (HL), seeking the optimal balance between efficacy and toxicity. It's like searching for the most efficient route through a challenging desert, seeking the path that leads to a successful outcome with minimal risks. This study provides valuable insights for improving treatment strategies for high-risk HL.

A Journey Towards Hope in Cancer Treatment

This research underscores the importance of individualized treatment plans for patients with high-risk Hodgkin lymphoma (HL). It emphasizes the need for ongoing research to identify the most effective and least toxic therapeutic approaches. It's like developing a customized map for each patient, ensuring a safe and successful journey through the challenging landscape of cancer treatment.

Dr.Camel's Conclusion

The study compares two intensive chemotherapy regimens for high-risk Hodgkin lymphoma (HL), seeking to optimize treatment strategies for this challenging disease. The research provides valuable insights for improving patient outcomes and reducing treatment-related toxicities.

Date :
  1. Date Completed 2009-01-29
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

18988286

DOI: Digital Object Identifier

10.1002/cncr.23979

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.